# Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL

> **NCT01722487** · PHASE3 · COMPLETED · sponsor: **Pharmacyclics LLC.** · enrollment: 269 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma

## Interventions

- **DRUG:** Ibrutinib
- **DRUG:** Chlorambucil

## Key facts

- **NCT ID:** NCT01722487
- **Lead sponsor:** Pharmacyclics LLC.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03
- **Primary completion:** 2015-05
- **Final completion:** 2015-05
- **Target enrollment:** 269 (ACTUAL)
- **Last updated:** 2017-11-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01722487

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01722487, "Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL". Retrieved via AI Analytics 2026-09-26 from https://api.ai-analytics.org/clinical/NCT01722487. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*